AFT signs North American licensing deal for Pascomer topical treatment

AFT signs North American licensing deal for Pascomer topical treatment
Paul McBeth
By Paul McBeth July 5 (BusinessDesk) - AFT Pharmaceuticals is eyeing a US$10 million payment from a North America licensing deal but is keeping its earnings guidance unchanged for now.  The maker of Maxigesic painkillers reached the licensing and development agreement with US-based Timber Pharmaceuticals for its Pascomer drug, which treats skin lesions known as facial angiofibromas associated with the genetic disorder, tuberous sclerosis.  Timber will cover the cost of two clinical trials involving 120 patients, with the results due ne...

More Services

Airwork on the block to repay $145m of bank debt
Law & Regulation

Airwork on the block to repay $145m of bank debt

Airwork has an outstanding intercompany loan of $35.83m, owes trade creditors $219,000.

Denise McNabb 11 Sep 2025
Risky Business: understanding NZ’s insurance sector
Services Editor’s note

Risky Business: understanding NZ’s insurance sector

BusinessDesk’s latest special project.

Victoria Young 11 Sep 2025
Assessing Spark's datacentre deal with PEP
Markets Analysis

Assessing Spark's datacentre deal with PEP

Could Spark be paying special dividends before the end of the decade?

Pattrick Smellie 13 Aug 2025
Food Chain report shows $9m owing
Services

Food Chain report shows $9m owing

More than $9.1m is owing in the liquidation of food supplier Food Chain, the first report in the insolvency shows. The company, which has ceased trading, had approximately 60 staff, and is also in receivership. The first liquidators' report of Adam Botterill and Damien Grant...

Staff reporters 11 Jul 2025